ストックスクリーナーアプリを入手
1.59
26.19%
0.33
前日終値:
$1.26
開ける：
$1.28
24時間の取引高:
2.61M
Relative Volume:
1.78
時価総額：
$208.75M
収益：
-
当期純損益:
$-217.44M
株価収益率:
-0.7327
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
+22.31%
1か月 パフォーマンス:
+28.23%
6か月 パフォーマンス:
-52.47%
1年 パフォーマンス:
-77.41%
1日の値動き範囲:
$1.2329
$1.60
1週間の範囲:
$1.18
$1.60
52週間の値動き範囲:
$1.115
$8.27
Prime Medicine Inc Stock (PRME) Company Profile
PRME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.59 | 170.68M | 0 | -217.44M | -205.20M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Analysts Set Expectations for Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a Buy - TipRanks
Prime Medicine, Inc. (NYSE:PRME) Receives $13.14 Average Target Price from Analysts - Defense World
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays PLC Buys 12,924 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc.: Buy Rating Backed by Promising Gene Editing Advancements and Robust Pipeline - TipRanks
Prime Medicine Reports Q1 2025 Financial Results - TipRanks
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Prime Medicine (PRME) Projects Funding Sufficiency Through Mid-2 - GuruFocus
Prime Medicine, Inc. SEC 10-Q Report - TradingView
PRIME MEDICINE Earnings Preview: Recent $PRME Insider Trading, Hedge Fund Activity, and More - Nasdaq
Prime Medicine Inc (PRME) Stock: A Year of Declines and Increases - investchronicle.com
Prime Medicine Inc (PRME)’s Day in Review: Closing at 1.60, Down by -3.61 - DWinneX
Stocks of Prime Medicine Inc (PRME) are poised to climb above their peers - Sete News
Is Prime Medicine Inc (PRME) a good investment opportunity? - uspostnews.com
Prime Medicine Inc (PRME) gets rating Initiated from JMP Securities - knoxdaily.com
Investor’s Delight: Prime Medicine Inc (PRME) Closes Weak at 1.41, Down -12.42 - DWinneX
Geode Capital Management LLC Raises Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha
Top investors say Prime Medicine Inc (PRME) ticks everything they need - Sete News
Breaking down PRME’s current quarter earnings estimates - uspostnews.com
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.38 - Defense World
11,426 Shares in Prime Medicine, Inc. (NYSE:PRME) Acquired by American Century Companies Inc. - Defense World
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga
There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News
Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World
Wedbush Estimates Prime Medicine FY2029 Earnings - The AM Reporter
Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World
Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Why Prime Medicine Stock Was Climbing Higher This Week - AOL.com
Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener
Why Prime Medicine Stock Is Soaring Today - Yahoo
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech
Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks
Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World
Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks
Prime Medicine advances AATD gene editing therapy - Investing.com India
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks
Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):